Are We Measuring the Right Outcomes? Rethinking Clinical Endpoint for the Next Generation of Therapies

Session details:

As innovation accelerates, endpoint strategies are under pressure to evolve. In oncology trials, surrogate endpoints like MRD are enabling faster-decision making, while cardiometabolic trials remain anchored in hard outcomes such as MACE and mortality. This fireside chat will challenge conventional thinking and explore how endpoint strategies must evolve in an era of scientific precision.